TRKA (F589L)
Sign in to save this workspaceNTRK1 · Variant type: point · HGVS: p.F589L
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Entrectinib | 99.6% | 0.4% | 93.69 |
| 2 | Pralsetinib | 99.4% | 0.6% | 93.43 |
| 3 | Alpelisib | 99.0% | 1.0% | 97.22 |
| 4 | Repotrectinib | 98.3% | 1.7% | 84.21 |
| 5 | Tenalisib | 97.7% | 2.4% | 97.98 |
| 6 | Nintedanib | 97.2% | 2.8% | 90.23 |
| 7 | Gilteritinib | 96.5% | 3.5% | 88.97 |
| 8 | Crizotinib | 96.0% | 4.0% | 91.39 |
| 9 | Lorlatinib | 94.8% | 5.2% | 97.24 |
| 10 | Ponatinib | 94.6% | 5.4% | 78.23 |
| 11 | Defactinib | 94.5% | 5.5% | 92.68 |
| 12 | Tivozanib | 93.8% | 6.2% | 92.42 |
| 13 | Sunitinib | 92.8% | 7.2% | 91.73 |
| 14 | Pacritinib | 92.2% | 7.8% | 88.64 |
| 15 | Ripretinib | 91.1% | 8.9% | 92.95 |
| 16 | Cabozantinib | 90.0% | 10.0% | 92.73 |
| 17 | Fedratinib | 86.6% | 13.4% | 96.21 |
| 18 | Alectinib | 78.1% | 21.9% | 95.49 |
| 19 | Brigatinib | 77.1% | 22.9% | 82.96 |
| 20 | Futibatinib | 69.6% | 30.4% | 98.48 |
| 21 | Axitinib | 67.4% | 32.6% | 93.23 |
| 22 | Bosutinib | 65.2% | 34.8% | 87.22 |
| 23 | Regorafenib | 64.7% | 35.3% | 95.99 |
| 24 | Selpercatinib | 55.2% | 44.8% | 96.72 |
| 25 | Ruxolitinib | 54.5% | 45.5% | 98.25 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Entrectinib | 99.6% | 99.0% | +0.6% |
| Pralsetinib | 99.4% | 98.7% | +0.8% |
| Alpelisib | 99.0% | 97.5% | +1.5% |
| Repotrectinib | 98.3% | 98.9% | -0.6% |
| Tenalisib | 97.7% | 59.0% | +38.6% |
| Nintedanib | 97.2% | 93.8% | +3.4% |
| Gilteritinib | 96.5% | 92.6% | +3.8% |
| Crizotinib | 96.0% | 95.8% | +0.2% |
| Lorlatinib | 94.8% | 63.2% | +31.6% |
| Ponatinib | 94.6% | 98.4% | -3.8% |
| Defactinib | 94.5% | 80.3% | +14.2% |
| Tivozanib | 93.8% | 85.7% | +8.2% |
| Sunitinib | 92.8% | 82.8% | +10.1% |
| Pacritinib | 92.2% | 89.4% | +2.7% |
| Ripretinib | 91.1% | 93.6% | -2.5% |
| Cabozantinib | 90.0% | 93.6% | -3.6% |
| Fedratinib | 86.6% | 56.2% | +30.4% |
| Alectinib | 78.1% | — | — |
| Brigatinib | 77.1% | — | — |
| Futibatinib | 69.6% | — | — |
| Axitinib | 67.4% | — | — |
| Bosutinib | 65.2% | 67.0% | -1.8% |
| Regorafenib | 64.7% | — | — |
| Selpercatinib | 55.2% | — | — |
| Ruxolitinib | 54.5% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.4ms